CN107961371A - Season influenza-RSV combined vaccine and its preparation method and application - Google Patents
Season influenza-RSV combined vaccine and its preparation method and application Download PDFInfo
- Publication number
- CN107961371A CN107961371A CN201710585420.4A CN201710585420A CN107961371A CN 107961371 A CN107961371 A CN 107961371A CN 201710585420 A CN201710585420 A CN 201710585420A CN 107961371 A CN107961371 A CN 107961371A
- Authority
- CN
- China
- Prior art keywords
- rsv
- influenza
- protein
- virus
- season
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 69
- 206010022000 influenza Diseases 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000002671 adjuvant Substances 0.000 claims abstract description 34
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 31
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 31
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 31
- 241000700605 Viruses Species 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000000568 immunological adjuvant Substances 0.000 claims abstract description 6
- 108700010900 influenza virus proteins Proteins 0.000 claims abstract description 5
- 230000006798 recombination Effects 0.000 claims abstract description 4
- 238000005215 recombination Methods 0.000 claims abstract description 4
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 108020000999 Viral RNA Proteins 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 101710172711 Structural protein Proteins 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 238000013519 translation Methods 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 101150046652 M2 gene Proteins 0.000 claims description 3
- 108020005202 Viral DNA Proteins 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 108091005703 transmembrane proteins Proteins 0.000 claims description 3
- 102000035160 transmembrane proteins Human genes 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 108060003393 Granulin Proteins 0.000 claims 1
- 101150118742 NP gene Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 14
- 108091007433 antigens Proteins 0.000 abstract description 14
- 102000036639 antigens Human genes 0.000 abstract description 14
- 238000002649 immunization Methods 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 7
- 230000001900 immune effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 description 23
- 101150039699 M2-1 gene Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 101710154606 Hemagglutinin Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 13
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 13
- 101710176177 Protein A56 Proteins 0.000 description 13
- 239000000185 hemagglutinin Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 102000009016 Cholera Toxin Human genes 0.000 description 11
- 108010049048 Cholera Toxin Proteins 0.000 description 11
- 229960003971 influenza vaccine Drugs 0.000 description 11
- 244000000010 microbial pathogen Species 0.000 description 11
- 210000004400 mucous membrane Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000037797 influenza A Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 229940124679 RSV vaccine Drugs 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical class C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940031670 conjugate vaccine Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101150103632 M2-2 gene Proteins 0.000 description 2
- 101710175243 Major antigen Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 230000016173 B cell antigen processing and presentation Effects 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710110818 Dermonecrotic toxin Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101100028758 Influenza A virus (strain A/Swine/Wisconsin/1/1967 H1N1) PB1-F2 gene Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101150103639 PB1 gene Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 229940124968 Rubella virus vaccine Drugs 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 108010088716 attachment protein G Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 108010014562 cytotoxic necrotizing factor type 1 Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 231100000708 dermatoxin Toxicity 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000027436 macrophage antigen processing and presentation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000917 skin toxin Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of season influenza RSV combined vaccines and its preparation method and application, including:Season influenza virus protein and the fusion protein and immunologic adjuvant of Respiratory Syncytial Virus(RSV) (RSV).The fusion protein is selected from the well-conserved protein sequence of season influenza virus and Respiratory Syncytial Virus(RSV), and the fusion protein and immunologic adjuvant of structure are with (0.5~2):1 ratio mixing, obtains season influenza RSV combined vaccine.The recombination fusion protein that the present invention uses is as novel antigens, during oral nasal administration, causes the IgG in serum and the increase of mucosal system IgA antibody titre.Reacted it is an advantage of the invention that causing for the co-immunization of season influenza and RSV viruses, coordinate mucosal adjuvant, cause mucosa-immune, more enhance immune effect.
Description
Technical field
The present invention relates to a kind of season influenza-RSV combined vaccines and its preparation method and application, belong to biotechnology neck
Domain.
Background technology
First, pathogenic microorganism and vaccine
It can cause human body or animal body that the microorganism of infectious disease occurs, be known as pathogenic microorganism or pathogenic microorganisms.Infect
After referring to pathogenic microorganism intrusion body, in certain position growth, breeding, and cause a series of physiopathologic processes.When
After pathogenic microorganism intrusion body, pathogenic microorganism interacts with body, changes the activity and function of other side, therefore energy mutually
No to produce communicable diseases, on the one hand pathogenecity, that is, pathogenic or virulence depending on pathogenic microorganism, another aspect additionally depend on machine
Resistance, that is, immunity of body.Pathogenic bacteria causes the capacity of water of infection, is exactly the virulence or pathogenic of bacterium.Bacterial poison
The power of the presence or absence of power and virulence depends primarily upon its invasiveness, toxigenicity and the ability for causing hypersensitivity.
Bacteriogenic toxin can be divided into two major class of exotoxin and endotoxin.Exotoxin is pathogen during growth and breeding
A kind of metabolite of ambient environment is secreted into, is mainly produced by gram-positive bacteria, a small number of Gram-negative bacterias can also produce
It is raw.Its chemical composition is protein, and antigenicity is strong, and toxicity is also strong, but extremely unstable, sensitive to hot and some chemical substances, is held
It is vulnerable to destruction.It is common as:The tetanus toxin, suddenly that diphtherotoxin that corynebacterium diphtheriae produces, clostridium tetani produce
Botulinum toxin that enterotoxin, the clostridium botulinum of random vibrios generation produce etc..Most of gramnegative bacteriums can produce endotoxin,
Actually it is present in the outer layer of bacteria cell wall, belongs to the part of cell membrane, is not secreted into environment under normal circumstances
In, only just discharged after bacterolysis, thus referred to as endotoxin, its toxicity are lower than exotoxin, antigenicity is also weak.
The Different Individual of same organism, after they are contacted with pathogen, some illness, some is then safe and sound, reason
It is that the immunity of Different Individual is different.It is immune just to refer to the one of body identification and exclusion antigen foreign matter (such as pathogenic microorganism)
Kind aversion response.In general, it be to body favourable, in exception conditions, it is also possible to damage body.Human body is immunized
It is divided into nospecific immunity and specific immunity.Wherein specific immunity refer to body for a certain or a certain quasi-microorganism or
Special resistance caused by product.And to be scientist develop vaccine that body is produced specific immunity resistance cause of disease micro-
The biological products of human body infringement are usually prepared in biology in itself by pathogenic microorganism.Bacterium, virus and rickettsia
Vaccine is made in the pathogenic microorganisms such as family name's body, after injecting body, body is produced specificity or sensitization lymphocyte, secretion is anti-
Body, reaches specific immunity effect.
And vaccine is divided into therapeutic and two kinds preventative, disease is treated by therapeutic vaccine, and passes through preventative epidemic disease
Seedling protects infringement of the human body from invasive organism.By effort for many years, medical field has developed a variety of epidemic diseases
Seedling is to prevent, bacterium, virus and fungi etc., various diseases caused by infection, drastically increases the healthy water of the mankind
It is flat.The continuous development of biotechnology, promotes the variation of vaccine kind.There is inactivation disease to infectious disease caused by pre- anti-virus
The vaccine that malicious technological development comes out, such as Vaccinum Encephalitidis Epidemicae, polio vaccine, influenza vaccines;Attenuated virus technological development goes out
The attenuated live vaccine come, such as Rotavirus Vaccine, oral polio virus vaccine, measles virus vaccines, mumps virus
Vaccine, rubella virus vaccine and chicken pox vaccine etc..To prevent big point of the biology such as the useful proteins of bacterial infectious disease and polysaccharide
The bacterium class vaccine that sub- purification technique develops, as tetanus toxoid, diphtheria toxoid, pertussis toxoid and its Asia are thin
Born of the same parents' component, epidemic meningitis Streptococcus polysaccharides and 23 valency pneumococal polysaccharides etc..More advanced useful half chemical combination technology is opened
The prevention meningitis and the bacterial vaccine of pneumonia issued, such as popular influenzae type polysaccharide-protein conjugate vaccines, 7 valencys or
10 valency pneumococcal polysaccharide-protein conjugate vaccines and 4 valencys meningococcal polysacharide-albumen conjugate vaccines.By to biological skill
Art is continuously improved, and can develop more new generation vaccine products and human health is chosen to deal with different pathogenic microorganisms
War.
2nd, mucosa-immune
Mucosal immune system is distributed widely under respiratory tract, intestines and stomach, urogenital mucous membrane and at some exocrine glands
Lymphoid tissue, be the main place for performing local specific immune function.Body there are about 95% bacterium, virus and parasite
Infection all originate in mucous membrane surface.Mucosal immune system is first of immunization barrier of body resistance pathogen invasion, is had
The independent immune system of unique texture and function, has positive effect for the field planting and intrusion for preventing pathogen.It is different from biography
The immune system of system, mucosal immune system are a large amount of immunocyte and immune molecule disperses lamina proprias under mucosal epithelium or mucous membrane
(diffused lymphoid tissue), or the mucosa-associated lymphoid tissue being gathered into by single or multiple lymph follicles, body more than 50%
Lymphoid tissue and more than 80% immunocyte concentrate on mucosal immune system.Mucosa-immune can induce local mucous membrane generation point
The protection antibodies such as secreting property IgA (sIgA), IgM and IgG, and the mucous membrane that can induce other positions also produces sIgA, this is mucous membrane
The main mechanism of immanoprotection action.In addition, mucosa-immune also induces mucous membrane ctl response, and produce the CD4 of secretion IFN-C+
T cell, this is very important for the prevention and removing of pathogen intrusion.Therefore mucosa-immune is protection body from cause of disease
The important barrier that body is invaded, is of great significance in the design of vaccine.
Based on the vaccine of mucosa-immune since the immune of induction often reacts weaker, the duration is short, it is difficult to obtains preferable
Immune protective effect.It is now recognized that such as less immunogenic of recombinant protein, synthesis polypeptide and DNA antigens is important original
One of because, it is therefore desirable to try to improve the intensity of immune response, and also have some vaccines to need to change immune response type, with
Prominent mucosa-immune etc..The problem of these aspects, makes the use of adjuvant seem particularly urgent and important, therefore for mucosa-immune
The research of adjuvant has become a research hotspot of infection immunity and vaccines arts.At present, the Mucosal Adjuvants reported
It can be divided mainly into three classes:The first kind is bacterial substances, including albumen (mainly bacteriotoxin) and nucleic acid;Second class is various
Cell factor;Three classes are antigen delivery systems.
Most-often used as Mucosal Adjuvants in bacteriotoxin is E.coli LT (LT) and cholera
Toxin (CT), people have been carried out it more research.It is close connection toxin (zonula occludens toxin, Zot), thin
Cellular toxicity necrosin (cytotoxic necrotizing factor 1, CNF1) and dermotoxin
(dermonecrotic toxin, DNT) etc. be report recently there is the bacteriotoxin of mucosal adjuvant.LT and CT are
Bacteriotoxin, its nucleotide sequence homology about 80%, structure is also essentially identical.The special CD4 of the main inducing antigens of CT+Th2
Type cell, and LT then can induce the CD4 of mixing+Th1 and Th2 type cells.CT and LT is strong Mucosal Adjuvants, but by
Its application in vaccine for man field is hindered with toxicity in it, therefore is built and is removed toxicity or reduce toxicity, is retained at the same time
The mutant of adjuvant attribute is very necessary.
LT is one of certified most effective mucosa-immune original in humans and animals experiment so far.It can effectively be situated between
CD4 of the guide pin to LT+T cell and B cell reaction.Through alimentary canal approach (oral or stomach in approach) injection LT to mouse,
Hypersecretion and systemic antibody response are induced, substantial amounts of anti-LT can be found in Respiratory Tract of Mice secretion and small intestine contents
IgA antibody.Take small intestinal mucosa to cut into slices, substantial amounts of thick liquid cell can be seen in mucosa lamina propria aggregate nodules.LT inductions stick
Film secretory antibody response it is most strong be antigen deposition site, but be not limited to antigen deposition site, imitated in other mucous membranes
Position is answered also to have same response.
LT and LTB has good immunogenicity, and LTB, which contains, causes most of advantage of T specific antibody responses to resist
Former epitope, both of which can effectively start the T cell and B cell immune response of body generation locally and systemically, moreover it is possible to make T, B thin
Born of the same parents produce long-term anamnestic response.
3rd, season influenza and its epidemiology
Influenza virus is orthomyxoviridae family, is segmented minus-stranded rna virus.According to the nucleoprotein (NP) and matrix egg of virus
(M) antigenicity is different in vain, and influenza virus is divided into first/A types, second/Type B, third/c-type.Flu-A has height variation, Su Zhufan
The features such as extensive is enclosed, the threat to public health is maximum.Different according to the hemagglutinin (HA) of virus surface, influenza A virus can
It is divided into H1-16 hypotypes, according to neuraminidase NA differences, is divided into N1-9 hypotypes.Flu-A popular in crowd disease at present
Poison mainly has H1, H2, H3 and N1, N2 hypotypes, and novel influenza popular in crowd has 2009H1N1, H7N9 fowl in recent years
Influenza virus, the former causes flu outbreak, and the lethality of the latter is up to 27.2%.
Influenza A and Type B influenza virus are all containing 8 segmented negative sense single stranded RNAs.Influenza A gene
Group at least encodes 11 polypeptides.Genetic fragment 1-3 encodes 3 polypeptides, the RNA polymerase that composition viral RNA relies on.Fragment 1 is compiled
Code polymerase complex protein PB2.Other polymerase protein PB1 and PA is encoded by fragment 2 and fragment 3 respectively.It is in addition, some
The fragment 1 of influenza A strain also encodes a little albumen PB1-F2, is produced by another reading frame in PB1 code areas
Raw.Fragment 4 encodes hemagglutinin (HA) surface glycoprotein, participates in cell adherence and virus is entered cell in infection period.
Fragment 5 encodes nucleocapsid nucleoprotein (NP) polypeptide, this is a kind of major structural protein being connected with viral RNA.Fragment 6 encodes god
Through amidase (NA) envelope glycoprotein.Fragment 7 encodes two kinds of stromatins, is referred to as M1 and M2, is by through different modes montage
MRNA translation.Fragment 8 encodes NS1 and NS2 (NEP), this is two kinds of non-structural proteins, by the mRNA through other modes montage
Translation.
HA, NA glycoprotein play an important role in virus infection, reproduction process, and important antigen, can stimulate body
Produce neutrality protection antibody.HA is present in virus envelope surface in the form of homotrimer, is identified by antibody in host
Major antigen, it influenza virus invade before identification host cell receptor and it is in connection in favor of virus absorption and wear film,
HA precursors just have infectivity by host protein enzymatic lysis, influenza virus.Anti- HA antibody is that have currently used for assessment influenza vaccines
The important indicator of effect property, although anti-NA antibody can mitigate clinical symptoms, the previously color producing reaction based on β acetonformaldehydes acid, by
In, suitable high-volume examination poisonous, cumbersome using reagent, thus anti-NA antibody tests are not widely popularized.Nineteen ninety,
Enzyme chain immunodetection of the Claude R.Lambr é reports based on the detection of arachidonic acid combination galactolipin group, is subsequently found
Anti- HA antibody as and Virus Interaction, which can also influence the combination with NA in conformation, so that it is false positive anti-NA antibody occur
Property.2009, SandbulteMR research teams were used for anti-NA antibody using the virus-like particle (VLP) for containing only influenza virus NA
Detection, this method patent applied for, because the VLP yield of preparation is limited, may also have baculoviral, VLP technologies are lacked in system
The laboratory of weary grasp or vaccine producer are difficult to carry out.
Vaccine inoculation is the most effective mode that flu-prevention occurs and propagates.The influenza vaccines of existing market application mainly have
Three kinds:Inactivated virus vaccine, split vaccine, subunit vaccine.The influenza vaccines applied at present it is efficient 60%~
Between 85%, its major antigen composition is influenza virus memebrane protein HA and NA.These vaccines infect same subtype influenza virus pre-
It is anti-effective, but the protecting effect between different subtype virus is weaker.In addition, the speed of mutation of influenza virus is very fast, influenza
Vaccine will be replaced every year, and prepared by the production to vaccine causes inconvenience.The World Health Organization is according to the whole world then
Next year influenza vaccines production component is predicted and recommended to scope influenza virus situation of change, and the accuracy of prediction will be direct
The protective efficacy of vaccine is influenced, as prediction of failure will cause the potential threat of flu outbreak prevalence.Therefore, developing one kind has
The universal vaccine of extensive protective effect establishes rapidly community immunity screen for the unexpected outburst after reply influenza virus mutant
Barrier, blocks flu outbreak sprawling, has extremely important practical significance in terms of reducing its harmfulness.
FLUMist is a kind of attenuated live vaccine, and children and adult can be protected not to suffer from influenza.FLUMist vaccine strains, which contain, to be come
Come from HA the and NA genetic fragments of wild-type strain currently popular and from common main donor virus (common
Masterdonor virus) (MDV) six gene segments:PB1, PB2, PA, NP, M and NS.The A types influenza disease of FLUMist
The MDV (MDV-A) of strain be continuously reduce temperature under conditions of in primary chicken nephridial tissue culture by wild type A/Ann
Obtained from the serial passage of Arbor/6/60 Strain (A/AA/6/60).MDV-A can effectively be replicated at 25 DEG C (ca, it is cold suitable
Should), but its growth is suppressed (ts, temperature sensitive) in 38 DEG C and 39 DEG C.In addition, this virus is in infected ferret intrapulmonary
Not reproducible (att, attenuation).This temperature sensitive phenotype, which is believed to be, to be limited its position in human respiratory outside most cold-zone domain and answers
The reason for making and causing its toxicity to weaken.Animal model test and clinical test show that this characteristic is quite stable.With leading to
This ts phenotypes difference of the strains of influenza viruses of mutagenesis preparation is crossed, the ts characteristics of MDV-A in the hamster of infection by passing
This characteristic of generation or the separation strains through passage isolated from children will not reduce.
After influenza virus is normally due to touch the nasal cavity and respiratory mucosa of host, into host cell, virus is completed
The duplication and transcription of genome.Therefore the first line of defence as human immunity, the timely activation of mucosa-immune are flowed for prevention
The diseases such as sense have important practical significance.
4th, Respiratory Syncytial Virus(RSV) and its epidemiology
Respiratory infectious disease is still to cause one of main causes of death in the world so far, and influenza virus
(Influenza virus, FLU) and Respiratory Syncytial Virus(RSV) (Respiratory Syncytial Virus, RSV) are then weights
The respiratory pathogen wanted.At present, the existing safely and effectively different type vaccine of influenza, guarantee is provided for the prevention and control of influenza.
And RSV there is no effective vaccine, challenge proposed for its prevention and control due to autoimmune properties.RSV is to cause infant's lower respiratory tract
Most important cause of disease is infected, and causes the elderly and immune deficiency to be grown up and is in hospital and the major reason because of pneumonia death.According to system
Count, the infant within 6 months causes to be even as high as up to the childhood infection rate within 70%, 2 one full year of life in hospital because of rsv infection
99%.For RSV because its scope of causing a disease is wide, the state of an illness is occurred frequently, and can cause serious complication etc., is made safely to mankind's health and lives
Into serious threat.RSV vaccines are set to one of vaccine first developed by the World Health Organization.
RSV is under the jurisdiction of Paramyxoviridae Pneumovirus, is sub-thread minus-stranded rna virus.RSV full-length genomes about 15Kb, is compiled
10 kinds of major proteins of code, including three transmembrane proteins (G, F and SH), two stromatins (M and M2), three nucleocapsid proteins
(N, P and L) and two non-structural proteins (NS1 and NS2) are formed, wherein fusion protein F (Fusion protein, F) and attachment
Protein G (Attchment protein, G) is that RSV excitating organisms produce the most important virus protein of protection antibody.G-protein is high
Difference is spent, two hypotypes of A and B can be divided into according to G-protein antigenic specificity RSV;The F protein of RSV is highly conserved, mediate retroviral bag
The fusion of film and host cell membrane so that virus successfully invades host cell and can also cause the fusion between flanking cell plasma membrane
Promote the formation of external plasomidum.It can effectively prevent RSV for the neutralizing antibody of RSV F and G glycoprotein and infect again, therefore RSV
The virulence that F and G-protein have been acknowledged as RSV is caused a disease molecule and protective antigens.
For RSV, in the 1960s, the formalin-inactivated vaccine (FI-RSV) of the development such as Fulginiti VA
Too drastic cause 2 death of child due to inducing Th2 types and being immunized and end in failure.The research of RSV vaccines is concentrated mainly at present
Carrier bacterin, attenuated live vaccine, subunit vaccine, DNA vaccination, VLP vaccines, but can use so far without granted RSV vaccines.RSV
The research of vaccine is always the focus of international concern, from the RSV vaccines in existing development as it can be seen that injecting immune cannot produce
Give birth to effective mucous membrane and cell immune response and immune protective effect is limited, there are potential security and total length F, G for DNA vaccination
There are the bottleneck problems such as potential Th1/Th2 loss of equilibrium are urgently to be resolved hurrily for protein vaccine.In recent years, with influenza virus reverse genetics
Technology day is also ripe and the multiple protein carrier such as influenza vectors it is increasingly ripe, using carrier protein as delivery system successfully
The RSV vaccine candidates strain of research and development can produce Double immune protecting effect, and safe, easily operated, have wide hair
Exhibition prospect, is expected to provide new thinking for RSV vaccine researches.The beautiful pearl of pa of MedImmune companies of U.S. development and production
(palivizumab) mainly for 263-275 amino acids in RSVA type F protein epitopes II, as global first spy
The opposite sex is directed to the Humanized monoclonal antibodies of RSV F protein neutralizing epitopes, and the beautiful pearl of pa confirms that inoculation crowd can be significantly reduced
Natural infection rate, plays a significant role during the prevention of RSV and early intervention.Ratified by FDA at present, successfully on
City, takes the lead in finishing in the world RSV without Miao Kefang, the situation to past medical help.
Influenza virus since its antigenic (referring to HA and NA) continuously morphs, at this two classes antigen it is hand-made
Although standby influenza vaccines technology of preparing is more mature, high using degree, it prepares speed far away from the viral change friction speed of itself
Degree so that the immune range of existing influenza all-virus inactivated vaccine in use is very limited, it is difficult to which the new variation of covering produces
Influenza virus.Nucleocapsid protein (NP) and stromatin (M) are conservative structural proteins in influenza virus, in virus evolution mistake
Aberration rate is very low in journey, therefore has the feasibility of the research and development permanent vaccine of influenza in theory.
Applicant further study show that, the coating and capsid protein of the virus surface of Respiratory Syncytial Virus(RSV) (RSV)
(M2) also there is higher conservative, vaccine is prepared based on highly conserved albumen, can solve to exempt from existing RSV natural immunities
Epidemic disease memory time section, antigen are easy to be denatured, and cause the technical problem of patient's superinfection.
Easily trigger respiratory disease after influenza infection, clinically RSV takes place frequently with influenza mixed infection at present.Therefore
Research and develop it is a kind of can at the same time flu immunization virus and Respiratory Syncytial Virus(RSV) vaccine, can not only reduce inoculator economy and
Body burden, and can prevent in time because of influenza virus infection and caused by respiratory disease.
The content of the invention
In view of the above-mentioned problems existing in the prior art, the object of the present invention is to provide a kind of season influenza-RSV combined vaccines
And its preparation method and application.
For achieving the above object, the technical solution that season influenza-RSV combined vaccine of the invention uses is as follows:
A kind of season influenza-RSV combined vaccines, including:Season influenza virus protein and Respiratory Syncytial Virus(RSV) (RSV)
Fusion protein and immunologic adjuvant.The fusion protein is selected from the well-conserved albumen of season influenza virus and Respiratory Syncytial Virus(RSV)
Sequence, the fusion protein and immunologic adjuvant of structure are with (0.5~2):1 ratio mixing, obtains season influenza-RSV combined vaccine.
Preferably, season influenza virus protein is selected from for Flu-A structural proteins:PBI、PBZ、PA、HA、NA、NP、ML
And/or M.
Preferably, Respiratory Syncytial Virus(RSV) albumen is selected from least one of following albumen:Transmembrane protein G, F, SH;Matrix
Albumen M, M2;Nucleocapsid protein N, P, L.
It is highly preferred that fusion protein combines albumen for M2-1-NP, the nucleotide sequence such as sequence of M2-1-NP fusion proteins is encoded
List SEQ ID NO:Shown in 9, its amino acid sequence such as sequence table SEQ ID NO encoded:Shown in 10.
Further, the nucleotide sequence for encoding M2-1-NP fusion proteins is NP nucleotide sequences and M2-1 nucleotide sequences, NP cores
Acid sequence such as sequence table SEQ ID NO:Shown in 1, its amino acid sequence such as sequence table SEQ ID NO encoded:Shown in 2;M2-1
Nucleotide sequence such as sequence table SEQ ID NO:Shown in 3, its amino acid sequence such as sequence table SEQ ID NO encoded:Shown in 4.
Two pairs of primer sequences, the wherein primer sequence of NP nucleic acid are separately designed according to NP nucleotide sequences and M2-1 nucleotide sequences
Such as sequence table SEQ ID NO:Shown in 5 and 6, the primer sequence table such as sequence table SEQ ID NO of M2-1 nucleic acid:Shown in 7 and 8.
Preferably, adjuvant includes sero-immunity adjuvant and Mucosal Adjuvants.
It is highly preferred that sero-immunity adjuvant includes freund adjuvant;Mucosal Adjuvants include CT adjuvants.It is any can be with egg
White vaccine combination is considered as falling under the scope of the present invention using the adjuvant for playing enhancing immune effect.
The mixed proportion of joint albumen and adjuvant is 1:1.
The present invention another goal of the invention be to provide a kind of preparation method of season influenza-RSV combined vaccines, its
In:
s1:Kit is rapidly purified using viral RNA/DNA and extracts RSV and Influenza Virus RNA respectively, by what is extracted
RNA carries out reverse transcription (RT), NP and M2 gene magnifications are carried out by template of the cDNA products of reverse transcription;
s2:Design primer expands to obtain M2-1 genetic fragments, NP genetic fragments respectively, then using this two sections of genetic fragments as mould
Plate carries out the M2-1-NP full length fragments that PCR amplification is recombinated, and recycles M2-1-NP genetic fragments and pGEX-2T carriers, prepares
Recombinant plasmid pGEX-2T-M2-1-NP;
s3:Recombinant plasmid pGEX-2T-M2-1-NP translation tables are reached into bacterial strain, obtain recombination fusion protein M2-1-NP.
Preferably, the restriction enzyme site of M2-1 is I restriction enzyme sites of EcoR, and the restriction enzyme site of NP bases is I restriction enzyme sites of Xho.
Preferably, the bacterial strain that recombinant plasmid pGEX-2T-M2-1-NP translation tables reach is e. coli strain bl21.
The 3rd goal of the invention of the present invention is to protect a kind of season influenza-RSV combined vaccines preventing or treating season
Application in the medicine for the disease that throttling sense and Respiratory Syncytial Virus(RSV) induce.
Compared with prior art, the present invention uses the fusion protein of restructuring as novel antigens, while causes inoculator to produce
Life is directed to two kinds of viral immune responses.Coordinate mucosal adjuvant, during oral nasal administration, this vaccine can cause mucosa-immune, enhancing
Immune effect;And trigger the raising of the IgG and schneiderian membrance system IgA antibody titre in serum at the same time.And this vaccine construct is steady
Fixed, adverse reaction is few, and one time inoculating two kinds are immunized, vaccination ways simple and effective, and body and the economy for significantly reducing patient are negative
Load.
It is of the invention main by the use of comma bacillus (CT) as a kind of effective Mucosal Adjuvants, CT by with cell surface
GM1 combine, the immune response effect of body fight original can not only be strengthened, additionally it is possible to change the type of mucosal immune response, bag
Include the expression for the cell factor for promoting Th1 and Th2 type cell effects, CD8+The apoptosis and CD4 of T cell+The propagation of T cell;Make B
MHC II of cell activation, the increase of ICAM-1, CD25, CD40 developed by molecule, influence B cell and macrophage antigen processing and
Presentation pathway.
The fusion protein that the present invention uses, can not only cause for two kinds of viral immune responses at the same time, due to selection
Albumen be the highly conserved albumen of virus, therefore easily cause the immune response of full hypotype for a long time after being inoculated with, carry significantly
High immune effect, for the virus of the height variation such as influenza, causes the permanent vaccine of full hypotype immune response, really does
Sick preceding prevention has been arrived, inoculation crowd and inoculation scope has not only been expanded, extends inoculation time, there is good popularization and economy
Value, also provides a new research direction for vaccine research staff.
Brief description of the drawings
Fig. 1 is M2-1-NP fusion proteins gel electrophoresis figure provided by the invention.
Fig. 2 is the M2-1-NP fusion protein Ss DS-PAGE figures of the offer of the present invention.
Fig. 3 is M2-1-NP fusion proteins ELISA antiserum titre figures provided by the invention.
Embodiment
The present invention is made with reference to embodiment further in detail, intactly to illustrate.The embodiments described below is example
Property, it is only used for explaining the present invention, and be not considered as limiting the invention.
Experimental method in following embodiments, is conventional method unless otherwise specified.Reality used in following embodiments
Test material unless otherwise specified, be that market is commercially available.
RSVM2 genes are between F and L genes, containing two open reading frames, i.e. M2-1 and M2-2.M2-1 genes are complete
826 nucleotide are about, encode 195 amino acid, positioned at 5 ' ends of M2 genes, its 3 ' end is overlapping with M2-2 gene head ends,
M2-l is RSV peploses and capsid composition, and viral capsid is formed together with N, P albumen.
First, the clone of M2-1-NP fusion proteins and prokaryotic expression
NP nucleotide sequences (the Gene of A/California/07/2009 (H1N1) influenza virus recorded in Genebank
ID:23308125) CDS areas complete sequence, sequence such as sequence table SEQ ID NO:Shown in 1, its amino acid sequence such as SEQ encoded
ID NO:Shown in 2.Nucleotide sequence (the Gene ID of M2-1 albumen are encoded in RSV:1489826) such as sequence table SEQ ID NO:3 institutes
Show, its amino acid sequence such as SEQ ID NO encoded:Shown in 4.
According to M2CDS sequences (Gene ID in the full nucleotide sequences of the RSV recorded in Genebank:1489826), design is drawn
Thing is as follows:
M2-1-Fwd is followed successively by by 5 ' ends to 3 ' ends:I restriction enzyme sites of protection base EcoR -- M2-1 albumen n end sequences.Draw
Thing (such as sequence table SEQ ID NO:Shown in 5) it is specific as follows:
M2-1-Fwd:5’--TAAGAATTC--atgtcgcgaagaaatcctt-3’
M2-1-Rev is followed successively by by 5 ' ends to 3 ' ends:Protection base Eco311 restriction enzyme sites -- NP albumen n end sequences -- M2-
1 PROTEIN C terminal sequence.Primer (such as sequence table SEQ ID NO:Shown in 6) it is specific as follows:
M2-1-Rev:5’--CTAGGGTCTC--gtcttatgacacta-3’
The nucleocapsid protein (NP) of influenza virus is the major structural protein encoded by viral RNA fragment 5.Share 1497
Nucleotide, from the code area that 46~1542 are NP, encodes 498 amino acid.NP albumen and virus group RNA and varial polymerases
3 subunits PB1, PB2, PA be connected, form ribonucleocapsids albumen (RNP) complex, participate in the duplication and transcription of RNA,
Work in the assembling of virus and the building-up process of RNA.
According to the NP nucleotide sequences of A/California/07/2009 (H1N1) influenza virus recorded in Genebank
(Gene ID:23308125) CDS areas complete sequence, design primer are as follows:
NP-Fwd is followed successively by by 5 ' ends to 3 ' ends:Protection base -- Eco311 restriction enzyme sites -- M2-1 PROTEIN C terminal sequences --
NP albumen n end sequences.Primer (such as sequence table SEQ ID NO:Shown in 7) it is specific as follows:
NP-Fwd:5’-CTAGGGTCTC-taaatggcgtctcaaggcaccaaacgat-3’
NP-Rev is followed successively by by 5 ' ends to 3 ' ends:Protection base -- I restriction enzyme sites of Xho -- NP PROTEIN C terminal sequences.Primer
(such as sequence table SEQ ID NO:Shown in 8) it is specific as follows:
NP-Rev:5’-CGCTCGAG-tcaactgtcatactcct-3’
Kit is rapidly purified using viral RNA/DNA and extracts the RSV and RNA of influenza virus, the bacterium that will be extracted respectively
Body RNA carries out reverse transcription (RT), NP and M2 gene magnifications are carried out by template of the cDNA products of reverse transcription.
According to above-mentioned nucleotide sequence and primer sequence, NP nucleotide sequences and M2-1 nucleotide sequences are expanded respectively, expanded
After increasing, amplified production is examined in gel electrophoresis.As shown in Figure 1, band 1 is DNA Marker, band 2 is blank control, and band 3 is
NP amplified productions, size are about 1500bp, and band 4 is M2-1 amplified productions, and size is about 800bp, and band is clear, meets expection
Theoretical value.
According to above-mentioned primer, pGEX-2T is selected to build pGEX-2T-M2-1-NP plasmids as carrier.After being put up a bridge with primer
Amplification, amplified production is through double digestion, gel recycling M2-1-NP fragments and linear carrier pGEX-2T.Obtained after being inserted into successfully
M2-1-NP nucleotide sequences such as sequence table SEQ ID NO:Shown in 9, its amino acid sequence such as sequence table SEQ ID NO encoded:10
It is shown.Censorship after amplified production glue reclaim is sequenced, sequencing result is compared in NCBI websites, it is as a result completely correct.
Glue reclaim recycles PCR purpose fragments using freeze-thaw method, and a hole is pricked with EP bottom of the tube of No. 18 syringe needles in 0.5mL,
A hole is similarly pricked on lid.EP pipes with holes are put in a new 1.5mLEP pipe.Spread in gel imager
Clean preservative film, the gel after electrophoresis is placed on preservative film, observes the position of purpose band.It is careful with blade in the UV lamp
Purpose band is cut, is put into EP pipes with holes.The EP pipes of overlapping placement are centrifuged into 5min together.After centrifugation, film becomes broken, from band
The EP pipes in hole are dropped in following pipe, if still having glue not change in pipe above, then are centrifuged, until all glue all drops to down
In the pipe in face.Pipe above is taken away, the neutral phenol of the balance of equivalent is added in following EP pipes, is mixed.Put to -80 DEG C of refrigerators
Middle jelly 30min, then room temperature melt.Upper strata aqueous phase is drawn in centrifugation, is put into new EP pipes.The PCI of equivalent is added, is vortexed and mixes,
Centrifuge 5min.Supernatant is put into new centrifuge tube, adds the 3M sodium acetates of 1/10 volume, the absolute ethyl alcohol of 2.5 times of volumes, is mixed
Even, -20 DEG C of refrigerators place lh.12000rpm centrifuges 20min, then abandons supernatant.1mL70% ethanol, washing are added in EP pipes
Precipitation, centrifuges 5min, abandons supernatant.After drying to be precipitated, it is dissolved in spare in 10 μ L TE.
2nd, M2-1-NP combines clone and the prokaryotic expression of albumen
Glue is returned into product DNA ligase, 16 DEG C of conversion DH5a competent cells, monoclonal expands, after small upgrading grain,
I double digestion of EcoR I and Xho, the screening positive clone under amicillin resistance, then converts BL21 competent cells.IPTG
Induction, adds the X-gal of the IPTG and 15 μ L of 40 μ L 0.1mol/l, 37 DEG C of 12~16h of culture, and centrifuge collects thalline,
Carrying out ultrasonic bacteria breaking, collect albumen after through GST affinity chromatography column purifications, obtain recombination fusion protein.SDS-PAGE the result is shown in
Occur a band at 64kD, it is close with expected results.The results are shown in Figure 2 by SDS-PAGE, and band 1 is albumen Marker;Band 2
Combine albumen for the M2-1-NP after lyophilized.
Since M2-1-NP fusion proteins are excessive, generally it is present in inclusion bodies in induction bacterium, it is therefore desirable to will be a large amount of
The protein product of expression is suspended in 3% beta -mercaptoethanol of 4mL 8M urea (Tris0.01M), and piping and druming is uniform, stirs 2h,
10000rpm centrifuges 15min, takes supernatant.Chromatography is freezed after collecting and preserved.
3rd, M2-1-NP combines the immunological effect experiment of albumen
1st, fusion protein prepares
Freund adjuvant is added in M2-1-NP fusion protein systems, fusion protein presses 1 with freund adjuvant:1 volume ratio is mixed
Added after conjunction in beaker, 4 DEG C are emulsified completely with stirrer stirring at low speed to freund adjuvant.
By fusion protein and CT adjuvants (1mg/mL) by volume 1:1 mixing, gently shaking is uniformly mixed it.
Peritoneal immunity and mucosa-immune are carried out using fusion protein.Healthy BALB/c mouse is taken to be tested, peritoneal immunity
Combine each four groups of mucosa-immune group, be respectively joint protein immunization group, commercially available influenza vaccines immune group, RSV vaccine immunities group and
Negative control group.
Commercially available influenza vaccines selection inspires confidence in Luo Ke (influenza virus subunit vaccine, lot number 20110801) and is given birth to by day scholar's power Jenner
Thing technology (Tianjin) Co., Ltd produces, the F-G eggs of RSV vaccines selection liberation army microorganism epidemic research institute laboratory restructuring
White subunit vaccine, negative control compare for PBS with the mixing of adjuvant.
2nd, peritoneal immunity
2.1st, 20 BALB/C mices are randomly divided into 4 groups, and first to fourth group is joint protein immunization group, commercially available stream respectively
Influenza vaccine immune group, RSV vaccine immunities group and negative control group;
2.2nd, during first immunisation, by recombinant protein and Freund's complete adjuvant mixture through experimental mice is injected intraperitoneally, often
Only 200 μ L (containing 15 μ g recombinant proteins);At the same time with PBS and Freund's complete adjuvant mixture through control group mice is injected intraperitoneally, often
Only 200 μ L;
2.3rd, second week and the 3rd week after first immunisation, it is respectively that recombinant protein and freund 's incomplete adjuvant mixture is trans-abdominal
Chamber injects experimental mice, every 200 μ L (containing 15 μ g recombinant proteins);Passed through at the same time with PBS and freund 's incomplete adjuvant mixture
Control group mice, every 200 μ L are injected intraperitoneally.
3rd, mucosal immunity
3.1st, 20 BALB/C mices are randomly divided into 4 groups, the 5th group to the 8th group be joint protein immunization group respectively, it is commercially available
Influenza vaccines immune group, RSV vaccine immunities group and negative control group;
3.2nd, with 1.5% yellow Jackets intraperitoneal injection of anesthesia mouse, to mouse no longer activity, by recombinant protein and CT
Adjuvant mixture instills experimental mice nasal cavity, every 30 μ L (containing 15 μ g recombinant proteins) dropwise with sterile pipette tips, while uses PBS
With CT adjuvant mixture instillation control group mice nasal cavities, every 30 μ L;It is immunized once weekly, continuous immunity surrounding.
4th, sampling evaluation
4.1st, the collection of mice serum
Blood is taken through mouse orbit after a week in final immunization, separation serum (adopt by peritoneal immunity group and mucosal immunity group
Collection);With PBS by each group mice serum from 1:10000 start doubling dilution to 1:5120000, indirect ELISA detection antibody effect
Valency.Peritoneal immunity detection serum IgG titers (geometrical mean).
4.2nd, the collection final immunization of mouse salivary after a week, by carbachol through making its generation in Intraperitoneal injection Mice Body
Saliva, every mouse 30ul, saliva (collection of mucosal immunity group) is collected with sterile pipette tips;With PBS by each group mouse salivary from 1:
200 start doubling dilution to 1:25600, indirect ELISA detection antibody titer.Mucosa-immune detection saliva IgA titres (put down by geometry
Average).
Testing result is shown in Table 1, wherein first group to the 4th group detection serum IgG titers (1:), the 5th group to the 8th group inspection
Survey saliva IgA titres (1:).
Mice antibody titer table after 1 peritoneal immunity of table and mucosa-immune
Parallel 1 | Parallel 2 | Parallel 3 | Parallel 4 | Parallel 5 | |
First group | 22449 | 20378 | 27241 | 22337 | 23097 |
Second group | 27755 | 28476 | 28830 | 26532 | 26770 |
3rd group | 26803 | 26577 | 28719 | 25761 | 26879 |
4th group | 0 | 0 | 0 | 0 | 0 |
5th group | 12842 | 12569 | 11430 | 12907 | 13243 |
6th group | 4813 | 3906 | 5083 | 5611 | 6507 |
7th group | 3851 | 4044 | 3984 | 4077 | 3577 |
8th group | 0 | 0 | 0 | 0 | 0 |
As can be seen from Table 1, artificial synthesized M2-1-NP combines albumen compared with commercial available vaccines, can cause equal drop
The immune response of degree, and immune effect is good.
After the saliva of mucosa-immune is pressed gradient dilution, influence of the analysis antigen concentration to ELISA testing results, the 5th group
The results are shown in Figure 3, and antigen concentration and specific antibody IgA titres are in a linear relationship, illustrate that mucosa-immune stimulates successfully.
Finally be necessary described herein be:Above example is served only for making technical scheme further detailed
Ground explanation, it is impossible to be interpreted as limiting the scope of the invention, those skilled in the art's the above according to the present invention
Some the nonessential modifications and adaptations made belong to protection scope of the present invention.
SEQUENCE LISTING
<110>Wuhan Bo Wo bio tech ltd
<120>Season influenza-RSV combined vaccine and its preparation method and application
<130> 2017
<160> 10
<170> PatentIn version 3.5
<210> 1
<211> 1497
<212> DNA
<213> Unknown
<220>
<223>NP DNA sequence dnas
<400> 1
atggcgtctc aaggcaccaa acgatcatat gaacaaatgg agactggtgg ggagcgccag 60
gatgccacag aaatcagagc atctgtcgga agaatgattg gtggaatcgg gagattctac 120
atccaaatgt gcactgaact caaactcagt gattatgatg gacgactaat ccagaatagc 180
ataacaatag agaggatggt gctttctgct tttgatgaga gaagaaataa atacctagaa 240
gagcatccca gtgctgggaa ggaccctaag aaaacaggag gacccatata tagaagagta 300
gacggaaagt ggatgagaga actcatcctt tatgacaaag ragaaataag gagagtttgg 360
cgcctagcaa acaatggcga agatgcaaca gcaggtctta ctcatatcat gatttggcat 420
tccaacctga atgatgccac atatcagaga acaagagcgc ttgttcgcac cggaatggat 480
cccagaatgt gctctctaat gcaaggttca acacttccca gaaggtctgg tgccgcaggt 540
gctgcggtga aaggagttgg aacaatagca atggagttaa tcagaatgat caaacgtgga 600
atcaatgacc gaaatttctg gaggggtgaa aatggacgaa ggacaagggt tgcttatgaa 660
agaatgtgca atatcctcaa aggaaaattt caaacagctg cccagagggc aatgatggat 720
caagtaagag aaagtcgaaa cccaggaaac gctgagattg aagacctcat tttcctggca 780
cggtcagcac tcattctgag gggatcagtt gcacataaat cctgcctgcc tgcttgtgtg 840
tatgggcttg cagtagcaag tgggcatgac tttgaaaggg aagggtactc actggtcggg 900
atagacccat tcaaattact ccaaaacagc caagtggtca gcctgatgag accaaatgaa 960
aacccagctc acaagagtca attggtgtgg atggcatgcc actctgctgc atttgaagat 1020
ttaagagtat caagtttcat aagaggaaag aaagtgattc caagaggaaa gctttccaca 1080
agaggggtcc agattgcttc aaatgagaat gtggaaacca tggactccaa taccctggaa 1140
ctgagaagca gatactgggc cataaggacc aggagtggag gaaataccaa tcaacaaaag 1200
gcatccgcag gccagatcag tgtgcagcct acattctcag tgcagcggaa tctccctttt 1260
gaaagagcaa ccgttatggc agcattcagc gggaacaatg aaggacggac atccgacatg 1320
cgaacagaag ttataagaat gatggaaagt gcaaagccag aagatttgtc cttccagggg 1380
cggggagtct tcgagctctc ggacgaaaag gcaacgaacc cgatcgtgcc ttcctttgac 1440
atgagtaatg aagggtctta tttcttcgga gacaatgcag aggagtatga cagttga 1497
<210> 2
<211> 498
<212> Protein
<213> Unknown
<220>
<223>NP amino acid sequences
<400> 2
masqgtkrsy eqmetggerq dateirasvg rmiggigrfy iqmctelkls dydgrliqns 60
itiermvlsa fderrnkyle ehpsagkdpk ktggpiyrrv dgkwmrelil ydkxeirrvw 120
rlanngedat aglthimiwh snlndatyqr tralvrtgmd prmcslmqgs tlprrsgaag 180
aavkgvgtia melirmikrg indrnfwrge ngrrtrvaye rmcnilkgkf qtaaqrammd 240
qvresrnpgn aeiedlifla rsalilrgsv ahksclpacv yglavasghd feregyslvg 300
idpfkllqns qvvslmrpne npahksqlvw machsaafed lrvssfirgk kviprgklst 360
rgvqiasnen vetmdsntle lrsrywairt rsggntnqqk asagqisvqp tfsvqrnlpf 420
eratvmaafs gnnegrtsdm rtevirmmes akpedlsfqg rgvfelsdek atnpivpsfd 480
msnegsyffg dnaeeyds 498
<210> 3
<211> 780
<212> DNA
<213> Unknown
<220>
<223>M2-1 DNA sequence dnas
<400> 3
atgtcgcgaa gaaatccttg taaatttgag attagaggtc attgcttgaa tggtagaaga 60
tgtcactaca gtcataatta ctttgaatgg cctcctcatg ccttactagt gaggcaaaac 120
ttcatgttaa acaagatact caagtcaatg gacaaaagca tagacacttt gtctgaaata 180
agtggagctg ctgaactgga cagaacagaa gaatatgctc ttggtatagt tggagtgcta 240
gagagttaca taggatctat aaacaacata acaaaacaat cagcatgtgt tgctatgagt 300
aaacttctta ttgagatcaa tagtgatgac attaaaaagc tgagagataa tgaagaaccc 360
aattcaccta agataagagt gtacaatact gttatatcat acattgagag caatagaaaa 420
aacaacaagc aaacaatcca tctgctcaaa agactaccag cagacgtgct gaagaagaca 480
ataaaaaaca cattagatat ccacaaaagc ataatcataa gcaacccaaa agagtcaacc 540
gtgaatgatc aaaatgacca aaccaaaaat aatgatatta ccggataaat atccttgtag 600
tatatcatcc atattgattt caagtgaaag catgattgct acattcaatc ataaaaacat 660
attacaattt aaccataacc atttggataa ccaccagcgt ttattaaata atatatttga 720
tgaaattcat tggacaccta aaaacttatt agatgccact caacaatttc tccaacatct 780
<210> 4
<211> 90
<212> Protein
<213> Unknown
<220>
<223>M2-1 amino acid sequences
<400> 4
mtkpkimilp dkypcsissi lissesmiat fnhknilqfn hnhldnhqrl lnnifdeihw 60
tpknlldatq qflqhlnipe diytiyilvs 90
<210> 5
<211> 28
<212> DNA
<213> Unknown
<220>
<223>M2-1-Fwd primer sequences
<400> 5
taagaattca tgtcgcgaag aaatcctt 28
<210> 6
<211> 25
<212> DNA
<213> Unknown
<220>
<223>M2-1-Rev primer sequences
<400> 6
cgctcgagtc aactgtcata ctcct 25
<210> 7
<211> 38
<212> DNA
<213> Unknown
<220>
<223>NP-Fwd primer sequences
<400> 7
ctagggtctc taaatggcgt ctcaaggcac caaacgat 38
<210> 8
<211> 25
<212> DNA
<213> Unknown
<220>
<223>NP-Rev primer sequences
<400> 8
cgctcgagtc aactgtcata ctcct 25
<210> 9
<211> 2274
<212> DNA
<213> Unknown
<220>
<223> M2-1-NP DNA
<400> 9
atggcgtctc aaggcaccaa acgatcatat gaacaaatgg agactggtgg ggagcgccag 60
gatgccacag aaatcagagc atctgtcgga agaatgattg gtggaatcgg gagattctac 120
atccaaatgt gcactgaact caaactcagt gattatgatg gacgactaat ccagaatagc 180
ataacaatag agaggatggt gctttctgct tttgatgaga gaagaaataa atacctagaa 240
gagcatccca gtgctgggaa ggaccctaag aaaacaggag gacccatata tagaagagta 300
gacggaaagt ggatgagaga actcatcctt tatgacaaag ragaaataag gagagtttgg 360
cgcctagcaa acaatggcga agatgcaaca gcaggtctta ctcatatcat gatttggcat 420
tccaacctga atgatgccac atatcagaga acaagagcgc ttgttcgcac cggaatggat 480
cccagaatgt gctctctaat gcaaggttca acacttccca gaaggtctgg tgccgcaggt 540
gctgcggtga aaggagttgg aacaatagca atggagttaa tcagaatgat caaacgtgga 600
atcaatgacc gaaatttctg gaggggtgaa aatggacgaa ggacaagggt tgcttatgaa 660
agaatgtgca atatcctcaa aggaaaattt caaacagctg cccagagggc aatgatggat 720
caagtaagag aaagtcgaaa cccaggaaac gctgagattg aagacctcat tttcctggca 780
cggtcagcac tcattctgag gggatcagtt gcacataaat cctgcctgcc tgcttgtgtg 840
tatgggcttg cagtagcaag tgggcatgac tttgaaaggg aagggtactc actggtcggg 900
atagacccat tcaaattact ccaaaacagc caagtggtca gcctgatgag accaaatgaa 960
aacccagctc acaagagtca attggtgtgg atggcatgcc actctgctgc atttgaagat 1020
ttaagagtat caagtttcat aagaggaaag aaagtgattc caagaggaaa gctttccaca 1080
agaggggtcc agattgcttc aaatgagaat gtggaaacca tggactccaa taccctggaa 1140
ctgagaagca gatactgggc cataaggacc aggagtggag gaaataccaa tcaacaaaag 1200
gcatccgcag gccagatcag tgtgcagcct acattctcag tgcagcggaa tctccctttt 1260
gaaagagcaa ccgttatggc agcattcagc gggaacaatg aaggacggac atccgacatg 1320
cgaacagaag ttataagaat gatggaaagt gcaaagccag aagatttgtc cttccagggg 1380
cggggagtct tcgagctctc ggacgaaaag gcaacgaacc cgatcgtgcc ttcctttgac 1440
atgagtaatg aagggtctta tttcttcgga gacaatgcag aggagtatga cagtatgtcg 1500
cgaagaaatc cttgtaaatt tgagattaga ggtcattgct tgaatggtag aagatgtcac 1560
tacagtcata attactttga atggcctcct catgccttac tagtgaggca aaacttcatg 1620
ttaaacaaga tactcaagtc aatggacaaa agcatagaca ctttgtctga aataagtgga 1680
gctgctgaac tggacagaac agaagaatat gctcttggta tagttggagt gctagagagt 1740
tacataggat ctataaacaa cataacaaaa caatcagcat gtgttgctat gagtaaactt 1800
cttattgaga tcaatagtga tgacattaaa aagctgagag ataatgaaga acccaattca 1860
cctaagataa gagtgtacaa tactgttata tcatacattg agagcaatag aaaaaacaac 1920
aagcaaacaa tccatctgct caaaagacta ccagcagacg tgctgaagaa gacaataaaa 1980
aacacattag atatccacaa aagcataatc ataagcaacc caaaagagtc aaccgtgaat 2040
gatcaaaatg accaaaccaa aaataatgat attaccggat aaatatcctt gtagtatatc 2100
atccatattg atttcaagtg aaagcatgat tgctacattc aatcataaaa acatattaca 2160
atttaaccat aaccatttgg ataaccacca gcgtttatta aataatatat ttgatgaaat 2220
tcattggaca cctaaaaact tattagatgc cactcaacaa tttctccaac atct 2274
<210> 10
<211> 588
<212> Protein
<213> Unknown
<220>
<223>M2-1 amino acid sequences
<400> 10
masqgtkrsy eqmetggerq dateirasvg rmiggigrfy iqmctelkls dydgrliqns 60
itiermvlsa fderrnkyle ehpsagkdpk ktggpiyrrv dgkwmrelil ydkxeirrvw 120
rlanngedat aglthimiwh snlndatyqr tralvrtgmd prmcslmqgs tlprrsgaag 180
aavkgvgtia melirmikrg indrnfwrge ngrrtrvaye rmcnilkgkf qtaaqrammd 240
qvresrnpgn aeiedlifla rsalilrgsv ahksclpacv yglavasghd feregyslvg 300
idpfkllqns qvvslmrpne npahksqlvw machsaafed lrvssfirgk kviprgklst 360
rgvqiasnen vetmdsntle lrsrywairt rsggntnqqk asagqisvqp tfsvqrnlpf 420
eratvmaafs gnnegrtsdm rtevirmmes akpedlsfqg rgvfelsdek atnpivpsfd 480
msnegsyffg dnaeeydsmt kpkimilpdk ypcsissili ssesmiatfn hknilqfnhn 540
hldnhqrlln nifdeihwtp knlldatqqf lqhlnipedi ytiyilvs 588
Claims (10)
- A kind of 1. season influenza-RSV combined vaccines, it is characterised in that including:Season influenza virus protein and respiratory syncystial disease The fusion protein and immunologic adjuvant of malicious (RSV), the fusion protein are selected from the height of season influenza virus and Respiratory Syncytial Virus(RSV) Conservative protein sequence, builds the albumen of fusion with immunologic adjuvant with (0.5~2):1 ratio mixing, obtain season influenza- RSV combined vaccines.
- 2. season influenza-RSV combined vaccines according to claim 1, it is characterised in that season influenza virus protein is first Type influenza structural proteins are selected from:PBI, PBZ, PA, HA, NA, NP, ML and/or M.
- 3. season influenza-RSV combined vaccines according to claim 1, it is characterised in that Respiratory Syncytial Virus(RSV) albumen selects From at least one of following albumen:Transmembrane protein G, F, SH;Matrix protein, M2;Nucleocapsid protein N, P, L.
- 4. season influenza-RSV combined vaccines according to claim 1, it is characterised in that:Joint albumen melts for M2-1-NP Hop protein.
- 5. season influenza-RSV combined vaccines according to claim 4, it is characterised in that:Encode M2-1-NP fusion proteins Nucleotide sequence such as sequence table SEQ ID NO:Shown in 9, its amino acid sequence such as sequence table SEQ ID NO encoded:Shown in 10.
- 6. season influenza-RSV combined vaccines according to claim 4, it is characterised in that:According to NP nucleotide sequences and M2-1 Nucleotide sequence separately designs two pairs of primer sequences, the wherein primer sequence of NP nucleic acid such as sequence table SEQ ID NO:Shown in 5 and 6, The primer sequence table of M2-1 nucleic acid such as sequence table SEQ ID NO:Shown in 7 and 8.
- 7. season influenza-RSV combined vaccines according to claim 1, it is characterised in that:Adjuvant is selected from sero-immunity adjuvant And Mucosal Adjuvants.
- 8. season influenza-RSV combined vaccines according to claim 1, it is characterised in that:The mixing of fusion protein and adjuvant Ratio is 1:1.
- 9. the preparation method of season influenza-RSV combined vaccines according to claim 1, it is characterised in that:s1:Kit is rapidly purified using viral RNA/DNA and extracts RSV and Influenza Virus RNA respectively, by the RNA extracted into Row reverse transcription (RT), NP and M2 gene magnifications are carried out by template of the cDNA products of reverse transcription;s2:Design primer expands to obtain respectively M2-1 genetic fragments, NP genetic fragments, then using this two sections of genetic fragments as template into The M2-1-NP full length fragments that row PCR amplification is recombinated, recycle M2-1-NP genetic fragments and pGEX-2T carriers, Prepare restructuring Plasmid pGEX-2T-M2-1-NP;s3:Recombinant plasmid pGEX-2T-M2-1-NP translation tables are reached into bacterial strain, obtain recombination fusion protein M2-1-NP.
- 10. season influenza-RSV combined vaccines according to claim 1 are in prevention or treat season influenza and respiratory tract conjunction Application in the medicine for the disease that cellular virus induces.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017102587324 | 2017-04-19 | ||
CN201710258732 | 2017-04-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107961371A true CN107961371A (en) | 2018-04-27 |
CN107961371B CN107961371B (en) | 2020-08-11 |
Family
ID=61996673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710585420.4A Active CN107961371B (en) | 2017-04-19 | 2017-07-18 | Seasonal influenza-RSV combined vaccine and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107961371B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
CN115925822A (en) * | 2022-09-01 | 2023-04-07 | 广州源博医药科技有限公司 | Recombinant protein and application thereof in preparation of respiratory syncytial virus vaccine |
CN116327910A (en) * | 2023-03-31 | 2023-06-27 | 北京吉诺卫生物科技有限公司 | Combination vaccine of novel coronavirus, influenza virus and/or RSV, preparation method and application thereof |
CN116650632A (en) * | 2023-03-31 | 2023-08-29 | 北京吉诺卫生物科技有限公司 | Combined vaccine of influenza virus and RSV (respiratory syncytial virus), preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2773637A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
CN103316357A (en) * | 2013-02-05 | 2013-09-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | Recombinant influenza virus chimeric vaccine carrying RSV gene, and preparation method thereof |
CN105101992A (en) * | 2013-02-11 | 2015-11-25 | 诺瓦瓦克斯股份有限公司 | Combination vaccine for respiratory syncytial virus and influenza |
CN105473157A (en) * | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | Combination vaccine |
-
2017
- 2017-07-18 CN CN201710585420.4A patent/CN107961371B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2773637A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
CN103316357A (en) * | 2013-02-05 | 2013-09-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | Recombinant influenza virus chimeric vaccine carrying RSV gene, and preparation method thereof |
CN105101992A (en) * | 2013-02-11 | 2015-11-25 | 诺瓦瓦克斯股份有限公司 | Combination vaccine for respiratory syncytial virus and influenza |
CN105473157A (en) * | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | Combination vaccine |
Non-Patent Citations (4)
Title |
---|
GARTEN,R.J.等: "GenBank: FJ969536.1", 《GENBANK》 * |
GRENINGER,A.L.等: "GenBank: KY674983.1", 《GENBANK》 * |
蔡若鹏 等: "甲型流感病毒NP和M2的特异性及其在疫苗研制中的应用", 《中国兽医学报》 * |
辛庆红: "呼吸道合胞病毒M2-1基因表达载体的构建及M2-1蛋白多克隆抗体的制备", 《万方数据库》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
CN115925822A (en) * | 2022-09-01 | 2023-04-07 | 广州源博医药科技有限公司 | Recombinant protein and application thereof in preparation of respiratory syncytial virus vaccine |
CN115925822B (en) * | 2022-09-01 | 2024-01-09 | 广州源博医药科技有限公司 | Recombinant protein and application thereof in preparation of respiratory syncytial virus vaccine |
CN116327910A (en) * | 2023-03-31 | 2023-06-27 | 北京吉诺卫生物科技有限公司 | Combination vaccine of novel coronavirus, influenza virus and/or RSV, preparation method and application thereof |
CN116650632A (en) * | 2023-03-31 | 2023-08-29 | 北京吉诺卫生物科技有限公司 | Combined vaccine of influenza virus and RSV (respiratory syncytial virus), preparation method and application thereof |
CN116650632B (en) * | 2023-03-31 | 2023-10-24 | 北京吉诺卫生物科技有限公司 | Combined vaccine of influenza virus and RSV (respiratory syncytial virus), preparation method and application thereof |
CN116327910B (en) * | 2023-03-31 | 2024-05-03 | 北京吉诺卫生物科技有限公司 | Combination vaccine of novel coronavirus, influenza virus and/or RSV, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN107961371B (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sui et al. | Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant | |
JP5327873B2 (en) | Recombinant Helicobacter pylori oral vaccine and preparation method thereof | |
Qu et al. | Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice | |
AU2006304895B2 (en) | Canine influenza virus and related compositions and methods of use | |
CN107961371A (en) | Season influenza-RSV combined vaccine and its preparation method and application | |
CN107109371A (en) | Pi Qinde virus reverses genetics systems and its application method | |
CN113943714B (en) | Callicarpa virus strain and application thereof | |
EP2442826A1 (en) | Influenza vaccine, composition, and methods of use | |
Alexandrova et al. | Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial | |
CN108823218A (en) | Chicken infectivity bursa of Fabricius virus VP 2 gene, its expression product, its subunit vaccine and application | |
CN106381290B (en) | Recombinate European fowl source H1N1 hypotype swine flu vaccine strain and its preparation method and application | |
CN104804099B (en) | A kind of reinforced polyepitope vaccines of recombination H9N2 subtype avian influenza | |
CN108619507A (en) | Respiratory Syncytial Virus(RSV)-epidemic meningitis combined vaccine and preparation method thereof | |
CN107050446B (en) | Modified seasonal influenza-RSV combination vaccine and method of making same | |
CN107964036A (en) | Respiratory Syncytial Virus(RSV) recombinant protein and its preparation method and application | |
Lublin et al. | Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins | |
CN107129527A (en) | A kind of Malian drainage protective antigens HP0623 and preparation method thereof | |
WO2015113188A1 (en) | Preparation of hadv chimeric vaccine with influenza virus as vector and application thereof | |
Ch'ng et al. | Immunogenicity of a truncated enterovirus 71 VP1 protein fused to a Newcastle disease virus nucleocapsid protein fragment in mice | |
Song et al. | Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets | |
CN108653726A (en) | RSV-PCV combined vaccines and preparation method thereof | |
RU2769672C1 (en) | Cold-adapted attenuation donor, strain of influenza virus b/sssr/60/69/5252, intended for production of strains of live intranasal influenza vaccine | |
RU2776196C1 (en) | Influenza virus strain influbact-h7/pspa for the production of a combined vaccine against influenza a virus and bacterial pneumonia caused by streptococcus pneumoniae | |
RU2776479C1 (en) | LIVE PROBIOTIC VACCINE CONTAINING CONSERVATIVE INFLUENZA A VIRUS EPITOPES (LAH+4M2e) FOR THE PREVENTION OF INFLUENZA INFECTION | |
CN104593386A (en) | Salmonella paratyphi ompN gene prokaryotic expression system and application of recombination expression protein thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Seasonal influenza RSV combined vaccine and its preparation method and application Granted publication date: 20200811 Pledgee: Shanghai Zhongmao Electromechanical Equipment Installation Co.,Ltd. Pledgor: BRAVOVAX Co.,Ltd.|SHANGHAI BOWO BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024310000711 |